Larimar Therapeutics (NASDAQ: LRMR) — Perfil da empresa, notícias e dados financeiros
Larimar Therapeutics is a biotech company developing therapies for rare diseases using unique protein replacement therapy.
Larimar Therapeutics
Larimar Therapeutics (NASDAQ:LRMR) is a biotechnology company dedicated to the development of innovative therapies for complex rare diseases. Using their unique protein replacement therapy platform, they are focused on advancing treatments that target the fundamental causes of these conditions. Their leading project, CTI-1601, is in clinical trials, aiming to treat Friedreich's ataxia, a debilitating, life-shortening neuromuscular disorder. Larimar's objective is to pioneer first-of-their-kind therapeutics to address unmet medical needs, ultimately improving the quality of life for patients with rare diseases. The company is committed to rigorous scientific research, strategic collaborations, and the pursuit of excellence in everything they do to bring groundbreaking therapies from the lab to the patients who need them most.
Resumo
Operações
Produtos e/ou serviços de Larimar Therapeutics
- CTI-1601, a potential treatment for Friedreich's Ataxia, aiming to deliver frataxin protein to mitochondria.
- Gene therapy platform, focusing on delivering genetic treatments for various mitochondrial diseases.
- Collaborations on research and development of therapies for rare diseases, enhancing the pipeline of treatments.
- Partnership programs for advancing drug discovery and development in the field of mitochondrial disorders.
- Investment in technology advancements to improve delivery mechanisms for genetic and protein-based therapies.
- Outreach and support initiatives for patients and families affected by rare diseases, providing education and resources.
equipe executiva do Larimar Therapeutics
- Carole S. Ben-MaimonCEO & Director
- Michael CelanoSecretary & CFO
- Gopi ShankarChief Development Officer
- John B. Harlow Jr.President & COO
- John BermanVice President of Finance & Administration
- Jennifer Spokes JohanssonVice President of Legal & Compliance
- Russell G. Clayton Sr.Chief Medical Officer
- Francis Michael ConwayVP & Controller
Últimas notícias sobre a Larimar Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Larimar Therapeutics, em USD.
- Cap. de mercado
- 248,3 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -2.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -172,5 mi | -165,7 mi | |
| 0 | -90,9 mi | -80,6 mi | |
| 0 | -41,8 mi | -36,9 mi | |
| 0 | -36,5 mi | -34,2 mi |